Nuwellis, Inc. (NASDAQ:NUWE) Short Interest Down 29.2% in January

Nuwellis, Inc. (NASDAQ:NUWE) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 5,056 shares, a decrease of 29.2% from the December 31st total of 7,144 shares. Based on an average daily trading volume, of 159,143 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.4% of the company’s stock are sold short. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 159,143 shares, the days-to-cover ratio is presently 0.0 days.

Nuwellis Stock Down 10.0%

Shares of NUWE stock opened at $3.77 on Friday. The business has a 50-day simple moving average of $2.30 and a 200-day simple moving average of $4.19. The stock has a market cap of $6.26 million, a PE ratio of -0.03 and a beta of -0.19. Nuwellis has a 52-week low of $1.71 and a 52-week high of $64.26.

Nuwellis (NASDAQ:NUWE) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of ($17.22) by $17.78. Nuwellis had a negative net margin of 202.83% and a negative return on equity of 1,367.63%. The firm had revenue of $2.22 million during the quarter, compared to analysts’ expectations of $2.50 million. Sell-side analysts anticipate that Nuwellis will post -8.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NUWE shares. Wall Street Zen downgraded shares of Nuwellis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.